NovaBridge Biosciences Names Physician-Executive Srishti Gupta as CEO
Event summary
- Dr. Srishti Gupta appointed CEO of NovaBridge Biosciences effective July 1, 2026.
- Xi-Yong (Sean) Fu steps down as CEO to pursue other opportunities but will remain in an advisory role during the transition.
- Gupta brings over two decades of leadership experience in biopharmaceuticals, global health, and strategy.
- Prior roles include CEO of Idorsia Ltd and leader of McKinsey & Company’s Global Health Practice.
The big picture
NovaBridge Biosciences is betting on Dr. Srishti Gupta's dual expertise as a physician and executive to accelerate the development of its clinical-stage assets, particularly givastomig and VIS-101. Her background in global health and strategic partnerships could be pivotal in navigating regulatory pathways and expanding market access. The appointment comes at a critical juncture for NovaBridge as it seeks to bridge the gap between scientific innovation and patient access.
What we're watching
- Strategic Partnerships
- How Gupta's experience in building large-scale public-private partnerships will impact NovaBridge's global reach and commercialization efforts.
- Clinical Milestones
- The pace at which givastomig and VIS-101 advance toward registration under Gupta's leadership.
- Operational Turnaround
- Whether Gupta can replicate her past success in executing operational and financial turnarounds at NovaBridge.